Literature DB >> 22843094

Posterior laryngitis: a study of persisting symptoms and health-related quality of life.

Hillevi Pendleton1, Marianne Ahlner-Elmqvist, Magnus Jannert, Bodil Ohlsson.   

Abstract

Posterior laryngitis is a common cause of chronic cough, hoarseness, voice fatigue and throat pain. The aim of the present study was to examine how patients with posterior laryngitis have been examined, treated and followed up, and to assess their present health-related quality of life (HRQOL). Patients treated for posterior laryngitis at consultation at the ear-, nose- and throat clinic during 2000-2008 were contacted by mail. The letter contained questionnaires addressing the current symptoms and medication, and the HRQOL 36-item short-form questionnaire (SF-36). Medical records were scrutinized. One hundred and twenty-two patients with verified signs and symptoms of posterior laryngitis were included. Forty percent of the patients had been treated for acid-related symptoms prior to consultation. The most common symptoms at the time of consultation were the sensation of hoarseness (women 40 %, men 37 %), globus (women 35 %, men 33 %) and cough (women 33 %, men 26 %). The most frequent diagnosis was gastro-oesophageal reflux disease. Ninety percent of the women and 92 % of the men were treated with proton pump inhibitors (PPIs). At the time of study, 63 % of the patients still had symptoms. The results of the SF-36 questionnaire showed significantly lower HRQOL for women. Patients with posterior laryngitis present varying symptoms, and are often not adequately treated or followed up. When PPI treatment fails, other aetiologies of their complaints, such as visceral hypersensitivity, weakly gaseous acid reflux or non-acid reflux are not considered. Symptoms from posterior laryngitis have a negative impact on the HRQOL for women.

Entities:  

Mesh:

Year:  2012        PMID: 22843094     DOI: 10.1007/s00405-012-2116-2

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  27 in total

Review 1.  Laryngopharyngeal reflux and voice disorders: an overview on disease mechanisms, treatments, and research advances.

Authors:  Robert T Sataloff; Mary J Hawkshaw; Reena Gupta
Journal:  Discov Med       Date:  2010-09       Impact factor: 2.970

Review 2.  Response of unexplained chest pain to proton pump inhibitor treatment in patients with and without objective evidence of gastro-oesophageal reflux disease.

Authors:  Peter J Kahrilas; Nesta Hughes; Colin W Howden
Journal:  Gut       Date:  2011-04-20       Impact factor: 23.059

3.  Health-related quality of life and psychological distress in a population-based sample of Swedish patients with inflammatory bowel disease.

Authors:  K Nordin; L Påhlman; K Larsson; M Sundberg-Hjelm; L Lööf
Journal:  Scand J Gastroenterol       Date:  2002-04       Impact factor: 2.423

Review 4.  Review article: reflux and its consequences--the laryngeal, pulmonary and oesophageal manifestations. Conference held in conjunction with the 9th International Symposium on Human Pepsin (ISHP) Kingston-upon-Hull, UK, 21-23 April 2010.

Authors:  J P Pearson; S Parikh; R C Orlando; N Johnston; J Allen; S P Tinling; N Johnston; P Belafsky; L F Arevalo; N Sharma; D O Castell; M Fox; S M Harding; A H Morice; M G Watson; M D Shields; N Bateman; W A McCallion; M P van Wijk; T G Wenzl; P D Karkos; P C Belafsky
Journal:  Aliment Pharmacol Ther       Date:  2011-04       Impact factor: 8.171

5.  Patients with irritable bowel syndrome and dysmotility express antibodies against gonadotropin-releasing hormone in serum.

Authors:  B Ohlsson; K Sjöberg; R Alm; G N Fredrikson
Journal:  Neurogastroenterol Motil       Date:  2011-06-30       Impact factor: 3.598

6.  Omeprazole does not reduce gastroesophageal reflux: new insights using multichannel intraluminal impedance technology.

Authors:  Anand P Tamhankar; Jeffrey H Peters; Giussepe Portale; Chih-Cheng Hsieh; Jeffrey A Hagen; Cedric G Bremner; Tom R DeMeester
Journal:  J Gastrointest Surg       Date:  2004-11       Impact factor: 3.452

7.  Relevance of norm values as part of the documentation of quality of life instruments for use in upper gastrointestinal disease.

Authors:  E Dimenäs; G Carlsson; H Glise; B Israelsson; I Wiklund
Journal:  Scand J Gastroenterol Suppl       Date:  1996

8.  Symptoms by age and sex. The population studies of men and women in Gothenburg, Sweden.

Authors:  G Tibblin; C Bengtsson; B Furunes; L Lapidus
Journal:  Scand J Prim Health Care       Date:  1990-03       Impact factor: 2.581

9.  The gastro-oesophageal reflux disease impact scale: a patient management tool for primary care.

Authors:  R Jones; K Coyne; I Wiklund
Journal:  Aliment Pharmacol Ther       Date:  2007-06-15       Impact factor: 8.171

10.  Symptoms, quality of life, videolaryngoscopy, and twenty-four-hour triple-probe pH monitoring in patients with typical and extraesophageal reflux.

Authors:  Eric S Powitzky; Leena Khaitan; C Gaelyn Garrett; William O Richards; Mark Courey
Journal:  Ann Otol Rhinol Laryngol       Date:  2003-10       Impact factor: 1.547

View more
  3 in total

1.  Potential anti-inflammatory effect of low-level laser therapy on the experimental reflux laryngitis: a preliminary study.

Authors:  Renata R Marinho; Renata M Matos; Jandson S Santos; Maria A G Ribeiro; Ronaldo A Ribeiro; Roberto C P Lima; Ricardo L C Albuquerque; Sara M Thomazzi
Journal:  Lasers Med Sci       Date:  2013-04-24       Impact factor: 3.161

2.  Posterior laryngitis: a disease with different aetiologies affecting health-related quality of life: a prospective case-control study.

Authors:  Hillevi Pendleton; Marianne Ahlner-Elmqvist; Rolf Olsson; Ola Thorsson; Oskar Hammar; Magnus Jannert; Bodil Ohlsson
Journal:  BMC Ear Nose Throat Disord       Date:  2013-09-09

3.  Antibodies against gonadotropin-releasing hormone in patients with posterior laryngitis.

Authors:  Hillevi Pendleton; Ragnar Alm; Gunilla Nordin Fredrikson; Bodil Ohlsson
Journal:  Drug Target Insights       Date:  2013-01-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.